

- **Name:** Dae Ho Lee
 - **Current Position & Affiliation:** Professor, University of Ulsan College of Medicine, Asan Medical Center
 - **Country:** Republic of Korea
-

• Educational Background:

- 1987.3. ~ 1994.2. M.D. College of Medicine, Seoul National University, Seoul, Republic of Korea
- 1999.3. ~ 2001.2. MS, Postgraduate School, Seoul National University, Seoul, Republic of Korea
- 2002. 9. ~ 2007.2. Ph.D Postgraduate School, Seoul National University, Seoul, Republic of Korea

• Professional Experience:

- 2002. 4 ~ 2006. 2. Medical Oncologist, Center for Specific Organs Cancer, National Cancer Center Hospital, Goyang, Gyeonggi-do, Republic of Korea
- 2003. 9 ~ 2006. 2. Medical Oncologist, Center for Lung Cancer, National Cancer Center Hospital, Goyang, Gyeonggi-do, Republic of Korea
- 2006. 3 – 2006. 8 Instructor, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
- 2006. 9. ~ 2011. 9. Assistant Professor, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
- 2011. 10 – 2017. 9. Associate Professor, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
- 2017.10 ~ present Professor, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

• Professional Organizations:

- Member, Korean Medical Association
- Member, Korean Association of Internal Medicine
- Member, Korean Cancer Association
- Member, Korean Society of Medical Oncology
- Member, Korean Cancer Study Group
- Member, Korean Association for Lung Cancer
- Member, Korean Association of Institutional Review Board
- Member, International Association for the Study of Lung Cancer
- Member, American Society of Clinical Oncology
- Member, American Association for Cancer Research
- Member, European Society for Medical Oncology

• Main Scientific Publications:

1. Cho BC, Han JY, Kim SW, Lee KH, Cho EK, Lee YG, Kim DW, Kim JH, Lee GW, Lee JS, Shim BY, Kim JS, Chun SH, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Lee Y, **Lee DH**, Kang JA, Lee N, Kwon MJ, Espenschied C, Yablonovitch A, Ahn MJ. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. *J Thorac Oncol.* 2021; 24:S1556-0864(21)03403-1.
2. Yoon S, Yang H, Ryu HM, Lee E, Jo Y, Seo S, Kim D, Lee CH, Kim W, Jung KH, Park SR, Choi EK, Kim SW, Park KS, **Lee DH**. Integrin $\alpha\beta 3$ Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer. *Cancer Res Treat.* 2021 Sep 30.
3. **Lee DH**. The Law Changes Behaviors: Is It Just Enough? *Cancer Res Treat.* 2021 Oct;53(4):895-896.
4. Horn L, Wang Z, Wu G, Poddubskaya E, Mok T, Reck M, Wakelee H, Chiappori AA, **Lee DH**, Breder V, Orlov S, Cicin I, Cheng Y, Liu Y, Fan Y, Whisenant JG, Zhou Y, Oertel V, Harrow K, Liang C, Mao L, Selvaggi G, Wu YL Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. *JAMA Oncol.* 2021;7(11):1617-1625.
5. Dziadziuszko R, Mok T, Peters S, Han JY, Alatorre-Alexander J, Leighl N, Sriuranpong V, Pérol M, de Castro Junior G, Nadal E, de Marinis F, Frontera OA, Tan DSW, **Lee DH**, Kim HR, Yan M, Riehl T, Schleifman E, Paul SM, Mocci S, Patel R, Assaf ZJ, Shames DS, Mathisen MS, Gadgeel SM Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. *J Thorac Oncol.* 2021 Dec;16(12):2040-2050.
6. Gainor JF, Curigliano G, Kim DW, **Lee DH**, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. *Lancet Oncol.* 2021 Jul;22(7):959-969.
7. Boyer M, Şendur MAN, Rodríguez-Abreu D, Park K, **Lee DH**, Çiçin I, Yumuk PF, Orlandi FJ, Leal TA, Molinier O, Soparattanapaisarn N, Langleben A, Califano R, Medgyasszay B, Hsia TC, Otterson GA, Xu L, Piperdi B, Samkari A, Reck M. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-small-Cell Lung Cancer With PD-L1 Tumor Proportion Score $\geq 50\%$: Randomized, Double-Blind Phase III KEYNOTE-598 Study ; KEYNOTE-598 Investigators. *J Clin Oncol.* 2021 Jul 20;39(21):2327-2338.
8. **Lee DH** Update of early phase clinical trials in cancer immunotherapy. *BMB Rep.* 2021 Jan;54(1):70-88.
9. Yu HA, Paz-Ares LG, Yang JC, Lee KH, Garrido P, Park K, Kim JH, **Lee DH**, Mao H, Wijayawardana SR, Gao L, Hozak RR, Chao BH, Planchard D. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer. *Clin Cancer Res.* 2021 Feb 15;27(4):992-1002.
10. Choi J, Lee HJ, Yoon S, Ryu HM, Lee E, Jo Y, Seo S, Kim D, Lee CH, Kim W, Ha JY, Kim SY, Gong G, Jung KH, Park SR, Kim SW, Park KS, **Lee DH**. Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer. *Am J Cancer Res.* 2020;10(9):2878-2894.
11. -Paz-Ares L, Kim TM, Vicente D, Felip E, **Lee DH**, Lee KH, Lin CC, Flor MJ, Di Nicola M, Alvarez RM, Dussault I, Helwig C, Ojalvo LS, Gulley JL, Cho BC. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. *J Thorac Oncol.* 2020 Jul;15(7):1210-1222.